Form 4: Castle Bio CEO Maetzold Reports Stock Transactions

Castle Biosciences CEO Derek J. Maetzold reported the exercise of performance-based stock units and subsequent tax-related share disposals, alongside various trust-related share transfers.

Summary

• CEO Derek J. Maetzold acquired 66,991 shares of Common Stock through the exercise of Performance-Based Stock Units (PSUs) at a price of $0.
• Concurrently, 23,972 shares of Common Stock were disposed of at $19.36 per share to cover tax liabilities related to the PSU vesting.
• Following these transactions, direct beneficial ownership stands at 112,702 shares.
• The filing also details significant indirect beneficial ownership through various trusts, including The Maetzold Descendants 2020 Trust (52,923 shares), Derek Maetzold 2020 Irrevocable Trust (44,986 shares), and several DJM Grantor Retained Annuity Trusts (totaling 148,900 shares across three trusts).
• Transfers occurred on July 11, 2025, involving 36,907 shares from DJM Grantor Annuity Trust No. 5 and 7,416 shares from DJM Grantor Annuity Trust No. 6 to direct holdings.
• An additional transfer on July 14, 2025, moved 44,323 shares from direct holdings to DJM Grantor Annuity Trust No. 7.
• The PSUs represent the remaining 50% of units granted on December 23, 2022, which fully vested on August 9, 2024.

Sentiment

Score: 7

Explanation: The filing indicates the vesting of performance-based stock units, which is a positive sign of executive compensation and potentially performance achievement. While there's a sale for tax purposes, it's a standard practice and doesn't necessarily indicate a negative outlook. The overall sentiment is neutral to slightly positive due to the underlying vesting event.

Positives

• Exercise of 66,991 Performance-Based Stock Units at a $0 cost, indicating successful vesting and achievement of performance criteria.
• Increase in direct beneficial ownership from the PSU exercise before tax withholding.

Negatives

• Disposal of 23,972 shares at $19.36 to cover tax obligations, reducing the net shares gained from the PSU exercise.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Indirect beneficial ownership through The Maetzold Descendants 2020 Trust, where the Reporting Person's spouse is trustee and spouse/children are beneficiaries.
• Indirect beneficial ownership through Derek Maetzold 2020 Irrevocable Trust, where the Reporting Person is trustee and his children are beneficiaries.
• Indirect beneficial ownership through The Maetzold 2018 Remainder Trusts (FBO Emily Carol Kirk, Hannah Elizabeth Maetzold, John Derek Maetzold, Peter Douglas Maetzold), where the Reporting Person is trustee and his children are beneficiaries.
• Indirect beneficial ownership through DJM Grantor Retained Annuity Trust No. 5, No. 6, and No. 7, where the Reporting Person is trustee and/or beneficiary, and other trusts are beneficiaries of No. 6.
• Transfers of shares between the Reporting Person's direct holdings and DJM Grantor Annuity Trusts.

Stakeholder Impact

• Shareholders: The transactions represent a routine part of executive compensation, specifically the vesting of performance-based stock units. The sale of shares for tax purposes is a common practice and does not necessarily indicate a change in management's confidence or a negative outlook for the company.
• Management/Employees: The vesting of PSUs indicates that performance targets, if any, were met, which can be a positive signal for employee morale and compensation structure effectiveness.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the exercise of performance-based stock units and a subsequent tax-related sale. Such transactions are common for executives and do not typically signal a change in the company's fundamental outlook or a shift in management's confidence. The net effect on the CEO's overall beneficial ownership, considering both direct and indirect holdings, remains substantial. Therefore, based solely on this filing, a 'hold' recommendation is appropriate as it provides no new information to warrant a change in investment thesis.

Keywords

Castle Biosciences, CSTL, SEC Form 4, Insider Trading, Stock Units, Executive Compensation, Derek Maetzold, Equity Transactions, Trusts, Beneficial Ownership